Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., May 2, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2018 and provided a corporate update. Total revenues were $3.5 million and net loss was $8.3 million for the three months ended […]
CUPERTINO, Calif., April 25, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH). DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in diseases
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis Read More »
CUPERTINO, Calif., April 24, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s(Nasdaq: DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of
DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call Read More »
CUPERTINO, Calif., March 29, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time. The call will feature a presentation by KOL Paul Kwo, MD, who will present an overview of alcoholic
DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis Read More »
CUPERTINO, Calif., March 20, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended release oxycodone CII). REMOXY® ER is designed as an
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER Read More »
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 1, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2017 and provided a corporate update. Total revenues were $19.5 million and net profit was $8.2 million for the three
CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC). DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several
CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast
DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call Read More »
CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a presentation by KOL Keith Lindor, MD, who will present an overview of
CUPERTINO, Calif., Feb. 14, 2018 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New Drug Application (NDA) for REMOXY® ER to the U.S. Food and Drug Administration (FDA). REMOXY ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone,
